| 000 | 01835 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516133343.0 | ||
| 264 | 0 | _c20130924 | |
| 008 | 201309s 0 0 eng d | ||
| 022 | _a1462-0332 | ||
| 024 | 7 |
_a10.1093/rheumatology/kes417 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFeist, Eugen | |
| 245 | 0 | 0 |
_aSmall molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis. _h[electronic resource] |
| 260 |
_bRheumatology (Oxford, England) _cAug 2013 |
||
| 300 |
_a1352-7 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Review | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAminopyridines |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdiagnosis |
| 650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aForecasting |
| 650 | 0 | 4 | _aGermany |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJanus Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 | _aMorpholines |
| 650 | 0 | 4 |
_aOxazines _xadministration & dosage |
| 650 | 0 | 4 |
_aPiperidines _xadministration & dosage |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 |
_aPyrimidines _xadministration & dosage |
| 650 | 0 | 4 |
_aPyrroles _xadministration & dosage |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBurmester, Gerd R | |
| 773 | 0 |
_tRheumatology (Oxford, England) _gvol. 52 _gno. 8 _gp. 1352-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/rheumatology/kes417 _zAvailable from publisher's website |
| 999 |
_c22474906 _d22474906 |
||